Search Medical Condition
Please enter condition
Please choose location from dropdown
Clear Trial Filters
 

Kfar Saba, Israel Clinical Trials

A listing of Kfar Saba, Israel clinical trials actively recruiting patients volunteers.

RESULTS

Found (25) clinical trials

Filling Bone Defects/Voids With Autologous BonoFill-II for Maxillofacial Bone Regeneration

Primary endpoint: The transplantation of BonoFill-II to the maxillary or mandible defect/void is safe under the following conditions: No chronic bone infection (Osteomyelitis); no significant changes in complete blood count (CBC) and in general health. Secondary endpoint: The transplantation of BonoFill-II to the maxillary or mandible void is efficient under ...

Phase

0.0 miles

Learn More »

Safety and Efficacy of AS101 1% Oral Solution in Patients With Neovascular Age-Related Macular Degeneration (AMD)

A Phase I/II, single-center, randomized double masked placebo controlled study to evaluate the safety and efficacy of AS101 1% oral solution or placebo once daily for 24 weeks in treating patients with neovascular AMD. Following confirmation of patient eligibility (as detailed in in the inclusion criteria), patients who meet all ...

Phase

0.0 miles

Learn More »

A Study of Pembrolizumab (MK-3475) in Pediatric Participants With an Advanced Solid Tumor or Lymphoma (MK-3475-051/KEYNOTE-051)

This is a two-part study of pembrolizumab (MK-3475) in pediatric participants who have any of the following types of cancer: advanced melanoma (6 months to <18 years of age), advanced, relapsed or refractory programmed death-ligand 1 (PD-L1)-positive malignant solid tumor or other lymphoma (6 months to <18 years of age), ...

Phase

2.39 miles

Learn More »

Efficacy and Safety of the Hcoil Deep TMS for the Treatment of Cannabis Addiction

Evaluation of efficacy and safety of H-coil deep transcranial magnetic stimulation 9 week treatment trial for cannabis addiction as assessed by measures of drug intake and craving.

Phase

2.39 miles

Learn More »

A Study of ND0801 in Attention Deficit/Hyperactivity Disorder (ADHD)

A multicenter, open label, escalating dose study to assess the tolerability and the safety and to explore the efficacy and the pharmacokinetics of ND0801 in adult patients with attention deficit/hyperactivity disorder (ADHD).

Phase

2.39 miles

Learn More »

A Two-part Single- and Repeat-dose Study of CSJ137 in Anemic Chronic Hemodialysis Patients

This posting discloses information about Part 1 of CCSJ137X2201. Another part, Part 2, of this trial is planned for conduct subsequent to the initiation of Part 1 and will have a different design than Part 1. The details of the design for this additional part are planned for disclosure in ...

Phase

6.61 miles

Learn More »

Safety and Pharmacokinetics of Cobimetinib in Pediatric and Young Adult Participants With Previously Treated Solid Tumors

This open-label, dose-escalation study is designed to evaluate the safety, tolerability, pharmacokinetics, and preliminary efficacy of cobimetinib in pediatric and young adult participants with solid tumors with known or potential kinase pathway activation for which standard therapy has proven to be ineffective or intolerable or for which no curative standard-of-care ...

Phase

6.61 miles

Learn More »

Safety and Efficacy Study of OpRegen for Treatment of Advanced Dry-Form Age-Related Macular Degeneration

OpRegen is a cell-based product composed of retinal pigment epithelial (RPE) cells, derived from human embryonic stem cells (hESC) and administered as a cell suspension in ophthalmic Balanced Salt Solution Plus (BSS Plus). This is a Phase I/IIa, dose-escalation, evaluating safety and tolerability of OpRegen transplantation to patients with progressive ...

Phase

6.61 miles

Learn More »

Therapy Protocol Acute Lymphoblastic Leukemia Stem Cell Transplantation International

To evaluate whether HSCT from matched family or unrelated donors (MD) is equivalent to the HSCT from matched sibling donors (MSD). To evaluate the efficacy of HSCT from mismatched family or unrelated donors (MMD) as compared to HSCT from MSD/MD. To determine whether therapy has been carried out according to ...

Phase

6.61 miles

Learn More »

A Study of Niraparib Combination Therapies for the Treatment of Metastatic Castration-Resistant Prostate Cancer

This multicenter study will evaluate safety and efficacy of niraparib in combination with other anti-cancer agents. The first combination study will combine niraparib with the anti-programmed cell death protein (PD)-1 monoclonal antibody, JNJ-63723283 (niraparib combination therapies) in participants with metastatic castration-resistant prostate cancer. This study will be conducted in 2 ...

Phase

6.61 miles

Learn More »